CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counse ...

CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after market close on September 22, 2025, it has been added to the Russell 2000® Index. This was part of the planned additions of select companies to this Index that had their IPO in the third quarter of 2025. “Carlsmed’s inclusion in the Russell 2000 Index is further validatio ...

财务表现 - 2025年第二季度收入1210万美元 同比增长99% [1][3] - 2025年第二季度毛利润890万美元 毛利率73.4% 较去年同期75.0%略有下降 [3] - 2025年第二季度运营费用1540万美元 研发费用420万美元 销售营销费用790万美元 行政管理费用330万美元 [3] - 2025年第二季度净亏损680万美元 调整后EBITDA亏损620万美元 [3] - 截至2025年6月30日现金及等价物3350万美元 7月IPO获得净融资9350万美元 [3] - 2025年全年收入指引4550-4750万美元 预计同比增长67%-75% [1][4] 业务进展 - aprevo人工智能脊柱手术平台采用率持续提升 推动商业表现强劲增长 [2] - 2025年7月成功完成首例个性化颈椎手术 预计2026年正式商业化推出 [2][3] - 颈椎手术获得CMS新技术附加支付(NTAP)报销资格 2025年10月1日生效 [3] - 收入增长主要源于2025年第二季度使用aprevo平台的手术数量增加 单台手术收入保持稳定 [3] 公司背景 - 专注于人工智能个性化脊柱手术解决方案的医疗技术公司 [10] - 致力于改善脊柱手术效果并降低医疗成本 [10]